Statement: the proportion of patients with slipped disks in cohort 2 of the primary clinical trial was equal to the proportion in cohort 1
Primary_evidence: Adverse Events 1:   Total: 5/101 (4.95%)   BILATERAL CATARACTS * 0/101 (0.00%)   APPENDICITIS * 2/101 (1.98%)   ISCHEMIC COLITIS * 1/101 (0.99%)   SLIPPED DISK * 0/101 (0.00%)   RIGHT BIMALLEOLAR ANKLE FRACTURE * 0/101 (0.00%)   ACUTE MYELOID LEUKEMIA * 0/101 (0.00%)   BREAST CANCER * 0/101 (0.00%)   PRIMARY DCIS IN BREAST * 0/101 (0.00%)   OVARIAN CYST * 1/101 (0.99%) Adverse Events 2:   Total: 9/98 (9.18%)   BILATERAL CATARACTS * 1/98 (1.02%)   APPENDICITIS * 0/98 (0.00%)   ISCHEMIC COLITIS * 0/98 (0.00%)   SLIPPED DISK * 1/98 (1.02%)   RIGHT BIMALLEOLAR ANKLE FRACTURE * 1/98 (1.02%)   ACUTE MYELOID LEUKEMIA * 1/98 (1.02%)   BREAST CANCER * 1/98 (1.02%)   PRIMARY DCIS IN BREAST * 1/98 (1.02%)   OVARIAN CYST * 1/98 (1.02%)